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cost of blood production accounted only for the resources expended for collection, 
processing, laboratory testing, storage, as well as the indirect donor’s productivity 
loss. Hence, the cost associated to donor recruitment, pre-transfusion preparation, 
transfusion administration, follow up management of adverse events, and other 
long-term relevant costs were not taken into consideration. Two separate question-
naires were used to collect data regarding: personnel time, annual blood quantities 
collected, percentage of wastage, consumables utilization, institutional overheads, 
information technology expenditure, medical equipment utilized, nuclear acid tests, 
other laboratory tests and indirect costs. Data gather by 53 hospitals across the 
country. An economic model was build using also economic data collected by the 
National School of Public Health and the Ministry of Health. All data referred to the 
year 2012. Results: The cost distribution was positively skewed (skewness:1.530). 
The unweighted mean cost of collecting a blood unit was estimated at € 146.43 
(standard deviation: +€ 28.18, min/max: € 110.25-€ 240.84). In addition, the indirect cost 
of donors’ loss of productivity was estimated at € 33,70 (+€ 49,23). Major cost compo-
nent appears to be the cost of personnel, which was estimated at € 46.86 (+€ 24.86, 
€ 16.49-€ 132.59), accounting for 32.0% of the total direct cost. The average of blood 
unit wastage was estimated at 4.90%. There were not differences between the cost 
of producing a unit of blood in Athens compared with the rest of the country (Man-
Whitney test, p-value: 0.341). ConClusions: This study indicates that the cost of 
producing a cost of blood isn’t insignificant. These figures need to be complemented 
with those concerning the cost of transfusion to have a full picture of producing 
and using a cost of blood locally.
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objeCtives: The significance of cystic fibrosis associated with early disability, 
the need for long-term regular treatment and follow-up and is associated with 
high costs. Data reflecting the socio-economic burden of cystic fibrosis in Russia is 
low, which dictates the need for clinical and economic studies, for example – this 
study. Methods: An assessment of the burden of cystic fibrosis with the use of 
tobramycin inhalation solution from different manufacturers and powder inhaled 
tobramycin (Tobi Podhaler) for the treatment of Pseudomonas infections in patients 
with cystic fibrosis. The study took into account only the direct medical costs of one 
patient based on standards of outpatient and inpatient care for patients with cystic 
fibrosis. Results: The burden of cystic fibrosis with the use of tobramycin powder 
for inhalation Tobi Podhaler with the time horizon of 10 years is reduced faster 
than in similar groups of patients: the point of profitability is on the eighth year of 
treatment when compared with tobramycin-Gobbi and a 9-year - with Bramitobom, 
when the use of Tobi Podhaler requires less cost to 46,372 USD and 50,138, respec-
tively. ConClusions: Additional costs are difficult to calculate due to the fact that 
tobramycin solution for inhalation requires compliance with ‘‘cold chain’’ at all 
stages of the life cycle of the product: transportation, storage at the distributor and 
at the pharmacy, storage at home. Thus, obtained data in controlled efficacy studies 
of tobramycin solution in actual practice, may be significantly lower.
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objeCtives: To evaluate the cost-effectiveness of prolonged release oxycodone/
naloxone combination tablets [OXN; naloxone is added to counteract opioid-induced 
constipation (OIC)] in patients who are constipated despite the use of two laxatives, 
compared with prolonged release oxycodone (OXY) alone. Methods: A model used 
data from one phase II randomised, controlled trial (RCT) in patients with moder-
ate/severe cancer pain and a pooled analysis of two phase III RCT’s in patients with 
moderate/severe non-cancer pain. A subgroup of patients with OIC who had failed on 
two or more laxatives at screening was applied in the analysis (n= 178). The drug cost 
for pain therapy was combined with laxative costs and other resources to calculate 
the cost difference between OXN and OXY. Quality-adjusted life-year (QALY) gains 
were calculated by mapping Bowel Function Index scores to EQ-5D utility values. 
Deterministic sensitivity analyses were performed. The analysis was conducted from 
the perspective of the UK National Health Service (NHS). Results: The incremental 
cost of OXN vs. OXY was £409.60 for the average treatment duration of 301 days. OXN 
gave an incremental QALY gain of 0.0524. The estimated incremental cost-effective-
ness ratio (ICER) was £7,821.80 for OXN vs. OXY. The ICER remained below £30,000 for 
all sensitivity analyses, with OXN dominating OXY in some scenarios when higher 
constipation unit costs were applied. ConClusions: Patients treated with OXN 
experienced a quality of life gain, and OXN had an ICER considerably below thresholds 
normally regarded as cost-effective in the UK (£20,000 – 30,000/QALY). More research 
is required into the cost of treating OIC, with OXN dominating OXY (total cost saving 
to the NHS and quality of life benefit) in sensitivity on OIC unit costs. OXN is therefore 
estimated to be a cost-effective option for treating patients with moderate to severe 
pain and OIC, who are constipated despite the use of two laxatives.
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Drug costs were based on the 10-μ g per hour buprenorphine patch and the equiv-
alent tramadol dose (2013 British National Formulary listings). Fracture costs 
were from a recent National Institute of Health and Care Excellence submission; 
utility weights were obtained from the literature. Results: For a population of 
100,000, the model predicted a reduction in the number of additional fractures 
(forearm, hip, or spine) associated with analgesic use from over 2,000 for patients 
treated with tramadol to under 20 for patients treated with buprenorphine. An 
estimated £5.5 million was saved and over 1,300 QALYs were gained. In sensitiv-
ity analysis, buprenorphine was dominant in most analyses and most sensitive 
to treatment duration. The cost-effectiveness estimate was below £20,000 per 
QALY in all scenarios. ConClusions: Our preliminary analysis suggests that 
buprenorphine has the potential to be dominant and cost-effective, compared 
with tramadol.
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objeCtives: Infantile Pompe disease is a rare metabolic disease. Enzyme replace-
ment therapy (ERT) has proven to have substantial effects on survival in infantile 
Pompe disease. However, costs of therapy are very high. This paper assesses the 
cost-effectiveness of ERT in infantile Pompe disease. Methods: A patient simula-
tion model was used to compare costs and effects of ERT with costs and effects 
of supportive therapy (ST). The model was filled with data on survival, quality of 
life and costs. For both arms of the model, data on survival were obtained from 
international literature. In addition, survival as observed among 20 infantile Dutch 
patients, who all received ERT, was used. Quality of life was assumed to be the 
same in both groups and was measured using the EQ-5D. Costs included the costs 
of ERT, which depend on a child’s weight, and costs of health care use, informal 
care and infusions. A lifetime time horizon was used, with semi-annual time 
cycles. Results: On average, ST receiving patients were modelled not to survive 
the first half year of life; whereas the life expectancy in the ERT patients was 
modelled to be almost 14 years. Lifetime incremental QALYs were 6.7. Incremental 
costs were estimated to be € 7.0 million, consisting for 95% of treatment costs. 
The incremental costs per QALY were estimated to be € 1.0 million. The incremen-
tal cost per life year gained was estimated to be € 0.5 million. ConClusions: In 
2012, the Dutch health care insurance board advised the Minister of Health to 
reimburse enzyme replacement therapy in Pompe disease, despite its unfavorable 
ICER. Other factors, such as the rarity of the disease, equity considerations, and 
the relatively modest budget impact have probably played a role in this decision. 
These and other factors could be incorporated in a formal multi-criteria decision 
analyses.
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objeCtives: To estimate the incremental cost-effectiveness (ICER) and cost-util-
ity ratio (ICUR) of belimumab compared to standard care (SC) for the treatment 
of patients with Systemic Lupus Erythematosus (SLE) in Portugal. Methods: A 
lifetime microsimulation model represented the complex and multidimensional 
course of SLE, based on long term data from a US cohort of SLE patients. The 
analysis was undertaken using a societal perspective with 5% discount rates 
for costs (direct and indirect costs), and effects [Life Years Gained (LYG) and 
QALY (Quality Adjusted Life Years)]. The model was calibrated with the phase 
III BLISS trials data, and UK utility values. The ICER and ICUR were estimated 
by comparison of SC vsSC with belimumab, with a lifetime analytic horizon. 
Belimumab non-responders were discontinued after 6 months and belimumab 
treatment was maximized at 3 years. Results: The model demonstrated that 
adding belimumab to SC to treat SLE patients with high disease activity, positive 
anti-dsDNA antibodies, and low complement (C3, C4) levels, would result in a 
potential gain of 0.41 life-years, and 0.32 QALYs. Incremental costs were€ 8,400, 
resulting in an ICER of € 20,649/LYG and ICUR of € 25,917/QALY for the base case 
scenario. ICER and ICUR are insensitive to the follow-up treatment costs of SLE, 
and wastage of drug; moderately sensitive to duration of treatment, and waning 
time; and very sensitive to discount rates, and exclusion of indirect costs. The 
probabilistic sensitivity analysis reveals a cost-effectiveness probability of 59% 
for a € 30,000/QALY threshold, and a median ICUR of € 27,932/QALY (95% confi-
dence interval: € 14,215/QALY - € 52,279/QALY). ConClusions: The analysis sug-
gests that adding belimumab to SC for SLE patients with high disease activity, 
positive anti-dsDNA, and low complement levels, is cost-effective, presenting 
an ICER and ICUR below the commonly used threshold. This study is funded by 
GlaxoSmithKline, protocol #HO-13-13626
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objeCtives: To estimate the cost of producing a unit of blood from a NHS and 
societal perspective in Greece. Methods: In line with the official guidelines, the 
